Prosecution Insights
Last updated: April 19, 2026

Kymab Limited

9 pending office actions

Portfolio Summary

9
Total Pending OAs
4
Final Rejections
5
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18616452 MULTISPECIFIC ANTIBODIES FOR IMMUNO-ONCOLOGY GILL, RACHEL B 1671 Final Rejection Mar 26, 2024
18592425 ANTI-PD-L1 AND IL-2 CYTOKINES ROONEY, NORA MAUREEN 1641 Non-Final OA Feb 29, 2024
18284952 THERAPEUTIC INHIBITORS OF GDF15 SIGNALLING LEE, YIE CHIA 1642 Non-Final OA Sep 29, 2023
18459995 ANTIBODIES, COMBINATIONS COMPRISING ANTIBODIES, BIOMARKERS, USES & METHODS HADDAD, MAHER M 1641 Final Rejection Sep 01, 2023
18364906 ANTIBODIES, USES & METHODS HADDAD, MAHER M 1641 Final Rejection Aug 03, 2023
18162043 Animal Models and Therapeutic Molecules SINGH, ANOOP KUMAR 1632 Final Rejection Jan 31, 2023
17727309 ANTI-ICOS ANTIBODIES OUSPENSKI, ILIA I 1644 Non-Final OA Apr 22, 2022
17725228 SYNERGISTIC COMBINATIONS OF OX40L ANTIBODIES FOR THE TREATMENT OF GVHD OUSPENSKI, ILIA I 1644 Non-Final OA Apr 20, 2022
16905537 Animal Models and Therapeutic Molecules SINGH, ANOOP KUMAR 1632 Non-Final OA Jun 18, 2020

Managing Kymab Limited's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month